The peptide problem: Hype is outrunning the evidence FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law BPC 157 (Body Protection Compound 157) Peptide for Tissue Repair & R ELITE BIO COMPOUNDS